Holen Sie sich die Stockscreener-App
55.96
1.04%
-0.59
Handel nachbörslich:
55.95
-0.010
-0.02%
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceutica - The National Law Review
Ionis Pharmaceuticals (IONS) Stock Analysis: Uncovering a Potential 62% Upside in the Biotech Sector - DirectorsTalk Interviews
Ionis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:IONS - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – DUS:ISI - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Connect - ACCESS Newswire
Ionis Pharmaceuticals Inc (IONS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ionis Pharmaceuticals Inc (IONS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Ionis Pharmaceuticals Inc (IONS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ionis Pharmaceuticals Inc (IONS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ionis Pharmaceuticals Inc (IONS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ionis Pharmaceuticals Inc. (IONS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
IONS|Ionis Pharmaceuticals Inc|Price:56.550|Chg%:+0.680 - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story - Yahoo Finance
Ionis stock trades steady as genetic medicine pipeline advances and revenue grows - Ad-hoc-news.de
Ionis Pharmaceuticals (IONS) Misses A Key Trial Endpoint, Is The Valuation Now Too Harsh? - Yahoo Finance
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23%HBSS - Morningstar
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $110 - Moomoo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc.IONS - PR Newswire
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock? - AAII
Canaccord reiterates Ionis stock rating on Tryngolza advantage By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Inc (IONS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Arrowhead rises on phase III hypertriglyceridemia readout - BioWorld News
Plozasiran Phase III Results Expand Cardiometabolic Use - AllSci
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug - BioPharma Dive
Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data - Fierce Pharma
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug - BioSpace
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR) - Seeking Alpha
Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline - Yahoo Finance
Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug - Seeking Alpha
Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Ionis Pharmaceuticals, Inc. (IONS) Shows Oversold Potential with Low RSI - GuruFocus
How does Biogen’s novel Alzheimer’s drug compare to approved drugs - MSN
2026-07-21 | Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:IONS | Press Release - Stockhouse
Ionis Pharmaceuticals Stock Slides 39% With A 9-Day Losing Spree - Trefis
Guggenheim cuts Ionis stock price target on Tryngolza sales outlook By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Stock Slides 39% Over 9 Straight Down Days - Trefis
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmac - The National Law Review
Ionis Pharmaceuticals Stock Slides 37% Over 8 Straight Down Days - Trefis
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Biotech Leader with a 70.90% Potential Upside - DirectorsTalk Interviews
Ionis Pharmaceuticals (IONS) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Stockholders to Learn More About the Investigation | NDAQ:IONS | Press Release - Stockhouse
(IONS) Risk Channels and Responsive Allocation - Stock Traders Daily
Ionis Pharmaceuticals (IONS) Proxy filing Summary - Quartr
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Cathie Wood Just Bet Big on This Biotech Stock - The Motley Fool
Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals (IONS) awards 3,399 RSUs to board director Reikes - Stock Titan
[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Ionis Pharmaceuticals (IONS) director receives 5,220 shares on RSU vesting - Stock Titan
Ionis Pharmaceuticals (IONS) director receives 5,220 shares from RSUs - Stock Titan
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’ - Stocktwits
Ionis Pharmaceuticals Stock Slides 37% Over 7 Straight Down Days - Trefis
7-Day Sell-Off Sends Ionis Pharmaceuticals Stock Down 37% - Trefis
Ionis (IONS) Begins First ION337 Trial In Dravet Syndrome Patients - Sahm
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Reach Out - ACCESS Newswire
Ionis Pharmaceuticals: The Heartbreak Is Priced In (NASDAQ:IONS) - Seeking Alpha
2026-07-16 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Reach Out | NDAQ:IONS | Press Release - Stockhouse
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):